Tradename | Company | Number | Date | Products |
---|---|---|---|---|
CYMBALTA | Eli Lilly | N-021427 RX | 2004-08-03 | 3 products, RLD, RS |
DRIZALMA SPRINKLE | Sun Pharmaceutical Industries | N-212516 RX | 2019-07-19 | 4 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
cymbalta | New Drug Application | 2023-08-18 |
drizalma sprinkle | New Drug Application | 2024-05-14 |
duloxetine | ANDA | 2024-10-18 |
duloxetine delayed-release | ANDA | 2017-04-21 |
duloxetine duloxetine | ANDA | 2024-04-08 |
duloxetine duloxetine hydrochloride | ANDA | 2017-08-14 |
duloxetine hcl | ANDA | 2023-03-24 |
duloxetine hydrochloride | ANDA | 2024-10-02 |
duloxetine hydrochloride delayed release | ANDA | 2019-03-14 |
duloxicaine | unapproved drug other | 2023-01-25 |
Expiration | Code | ||
---|---|---|---|
DULOXETINE HYDROCHLORIDE, CYMBALTA, LILLY | |||
2023-04-20 | NPP |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Depressive disorder | D003866 | EFO_1002014 | F32.A | 5 | 21 | 45 | 52 | 26 | 147 |
Depression | D003863 | — | F33.9 | 4 | 21 | 38 | 42 | 26 | 129 |
Major depressive disorder | D003865 | EFO_0003761 | F22 | 3 | 14 | 34 | 32 | 19 | 101 |
Fibromyalgia | D005356 | EFO_0005687 | M79.1 | 1 | 1 | 9 | 5 | 12 | 27 |
Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | 1 | 3 | 8 | 9 | 6 | 26 |
Myofascial pain syndromes | D009209 | EFO_1001054 | — | 1 | 1 | 8 | 5 | 11 | 25 |
Neuralgia | D009437 | EFO_0009430 | — | 1 | 5 | 3 | 7 | 8 | 24 |
Pain | D010146 | EFO_0003843 | R52 | — | 4 | 5 | 4 | 9 | 22 |
Diabetic neuropathies | D003929 | EFO_1000783 | — | 1 | 4 | 6 | 9 | 1 | 21 |
Knee osteoarthritis | D020370 | EFO_0004616 | M17 | 1 | 4 | 7 | 5 | 3 | 19 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | 2 | — | 2 | 4 |
Mood disorders | D019964 | EFO_0004247 | F30-F39 | 1 | — | 1 | — | 1 | 3 |
Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | 2 | 1 | — | 1 | 3 |
Neoplasms | D009369 | — | C80 | — | 2 | 1 | — | — | 3 |
Social phobia | D000072861 | EFO_1001917 | F40.1 | — | — | 1 | — | 2 | 3 |
Recurrence | D012008 | — | — | — | — | 2 | — | — | 2 |
Neurotoxicity syndromes | D020258 | — | G92 | — | 1 | 1 | — | — | 2 |
Hiv infections | D015658 | EFO_0000764 | B20 | — | 1 | 1 | — | — | 2 |
Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | 1 | — | 1 | 2 |
Colorectal neoplasms | D015179 | — | — | — | 2 | 1 | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Wounds and injuries | D014947 | — | T14.8 | — | 1 | — | — | 4 | 5 |
Alcoholism | D000437 | EFO_0003829 | F10.1 | 1 | 1 | — | — | — | 2 |
Brain injuries | D001930 | — | S06.9 | — | 1 | — | — | 1 | 2 |
Suicidal ideation | D059020 | EFO_0004320 | R45.851 | — | 1 | — | — | 1 | 2 |
Attention deficit disorder with hyperactivity | D001289 | EFO_0003888 | F90 | — | 1 | — | — | 1 | 2 |
Male infertility | D007248 | EFO_0004248 | N46 | — | 1 | — | — | — | 1 |
Infertility | D007246 | HP_0000789 | — | — | 1 | — | — | — | 1 |
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 1 | — | — | — | 1 |
Prediabetic state | D011236 | EFO_1001121 | R73.03 | — | 1 | — | — | — | 1 |
Insulin resistance | D007333 | HP_0000855 | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Substance-related disorders | D019966 | EFO_0003890 | F13 | 1 | — | — | — | 1 | 2 |
Therapeutic equivalency | D013810 | — | — | 2 | — | — | — | — | 2 |
Cocaine-related disorders | D019970 | — | F14 | 2 | — | — | — | — | 2 |
Drug interactions | D004347 | — | — | 1 | — | — | — | — | 1 |
Alcohol drinking | D000428 | EFO_0004329 | — | 1 | — | — | — | — | 1 |
Amphetamine-related disorders | D019969 | EFO_0004701 | F15 | 1 | — | — | — | — | 1 |
Hyperalgesia | D006930 | — | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Systemic scleroderma | D012595 | EFO_0000717 | M34.0 | — | — | — | — | 1 | 1 |
Localized scleroderma | D012594 | EFO_1001361 | L94.0 | — | — | — | — | 1 | 1 |
Diffuse scleroderma | D045743 | EFO_0000404 | — | — | — | — | — | 1 | 1 |
Pathologic constriction | D003251 | — | — | — | — | — | — | 1 | 1 |
Spinal stenosis | D013130 | EFO_0007490 | M48.0 | — | — | — | — | 1 | 1 |
Chemical and drug induced liver injury | D056486 | EFO_0004228 | — | — | — | — | — | 1 | 1 |
Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | — | — | — | 1 | 1 |
Psychological trauma | D000067073 | — | — | — | — | — | — | 1 | 1 |
Hyperbaric oxygenation | D006931 | — | — | — | — | — | — | 1 | 1 |
Pain management | D059408 | — | — | — | — | — | — | 1 | 1 |
Drug common name | Duloxetine |
INN | duloxetine |
Description | (S)-duloxetine is a duloxetine. It is an enantiomer of a (R)-duloxetine. |
Classification | Small molecule |
Drug class | antidepressants (fluoxetine type) |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CNCC[C@H](Oc1cccc2ccccc12)c1cccs1 |
PDB | — |
CAS-ID | 116539-59-4 |
RxCUI | — |
ChEMBL ID | CHEMBL1175 |
ChEBI ID | 36795 |
PubChem CID | 60835 |
DrugBank | DB00476 |
UNII ID | O5TNM5N07U (ChemIDplus, GSRS) |